Achillion raising $50 million to advance hepatitis C candidates
This article was originally published in Scrip
Executive Summary
Achillion Pharmaceuticals, a US company focused on the discovery and development of small-molecule drugs to combat infectious diseases, is raising around $50 million through the private placement of common stock and warrants to move forward its pipeline of antiviral candidates for hepatitis C.